Safety and immunogenicity of intradermal administration of fractional dose CoronaVac(®), ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination

There is a limited supply of COVID-19 vaccines, with less than 20% of eligible populations in low-income countries having received one dose. Intradermal delivery of fractional dose vaccines is one way to improve global vaccine access, but no studies have reported data on intradermal delivery of COVI...

Descripción completa

Detalles Bibliográficos
Autores principales: Chatsiricharoenkul, Somruedee, Niyomnaitham, Suvimol, Posen, Harry Joshua, Toh, Zheng Quan, Licciardi, Paul V., Wongprompitak, Patimaporn, Duangchinda, Thaneeya, Pakchotanon, Pattarakul, Chantima, Warangkana, Chokephaibulkit, Kulkanya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577032/
https://www.ncbi.nlm.nih.gov/pubmed/36268028
http://dx.doi.org/10.3389/fimmu.2022.1010835

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577032/
https://www.ncbi.nlm.nih.gov/pubmed/36268028
http://dx.doi.org/10.3389/fimmu.2022.1010835

Ejemplares similares